|Bid||15.60 x 800|
|Ask||15.61 x 1100|
|Day's Range||15.20 - 15.64|
|52 Week Range||11.44 - 17.62|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.93|
LONDON, UK / ACCESSWIRE / June 29, 2018 / If you want a free Stock Review on SRPT sign up now at www.wallstequities.com/registration. On Thursday, June 28, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Thursday's trading session in bullish territories.
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Amicus Therapeutics Inc (NASDAQ:FOLD), with a market capitalization of US$2.89b, rarely draw their attention from the investingRead More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 26) AngioDynamics, Inc. (NASDAQ: ANGO ) Chembio Diagnostics Inc ...
NEW YORK, NY / ACCESSWIRE / June 27, 2018 / U.S. markets rebounded on Tuesday after experiencing steep losses the past week due to growing trade tensions. The Dow Jones Industrial Average increased 0.12 ...
Amicus Therapeutics (FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, announced today regulatory and clinical advancements in its development program for AT-GAA for Pompe disease following guidance from regulators in the European Union as well as guidance on manufacturing and bio-comparability from German regulatory authorities (BfArM). 2) to discuss whether Amicus may pursue a pathway for AT-GAA that includes a conditional marketing approval (CMA) application in Europe. Amicus has concluded this series of interactions and has now received written guidance from the SAWP.
Amicus Therapeutics (FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced the election and appointment of the Company’s President and Chief Operating Officer Bradley L. Campbell to its Board of Directors, effective immediately. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, “On behalf of our Board of Directors, I am pleased to announce Bradley’s appointment to the Board.
CRANBURY, N.J., June 01, 2018-- Amicus Therapeutics, Inc. announced today that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the upcoming ...
Amicus Therapeutics (FOLD) has initiated the commercial launch of the oral small molecule pharmacological chaperone Galafold® capsules 123mg (migalastat) for treatment of patients aged 16 years and older with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency) and who have an amenable mutation. Galafold is the first and only oral precision medicine for Fabry disease in Japan. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, “The launch of Galafold in Japan, less than one year after our J-NDA submission, provides a significant opportunity for us to deliver this oral and differentiated precision medicine to amenable Fabry patients living in Japan.
NEW YORK, NY / ACCESSWIRE / May 25, 2018 / U.S. markets were weighed down by the energy sector on Thursday as U.S. crude oil prices closed lower for the third consecutive session. However, major indexes ...
Stock Research Monitor: AMPE, ANTH, and ARLZ LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want a free Stock Review on FOLD sign up now at www.wallstequities.com/registration . In today's pre-market ...
NEW YORK, NY / ACCESSWIRE / May 16, 2018 / U.S. markets slumped Tuesday, with the Dow Jones breaking an 8-day win streak, as interest rates surged to new highs. The Dow Jones Industrial Average declined 0.78 percent to close at 24,706.41, while the S&P 500 Index fell 0.68 percent to close at 2,711.45.
CRANBURY, N.J., May 09, 2018-- Amicus Therapeutics today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside chat at the Bank of America Merrill Lynch 2018 ...
Amicus Therapeutics Inc’s (NASDAQ:FOLD): Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The US$2.68B market-cap company announcedRead More...
The Cranbury, New Jersey-based company said it had a loss of 28 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was ...
Continued Global Galafold ® Adoption and Expansion– Reaffirms FY18 Revenue Guidance of $75 M- $85 M at Top End of Range. Significant Momentum with Pompe Clinical, Regulatory and Manufacturing Activities- ...
Amicus Therapeutics (FOLD) generated net product sales of $36.9 million in 2017 compared to $4.9 million in 2016. For 2018, 2019 and 2020, Amicus is expected to generate revenues of $85.3 million, $180.2 million, and $255.6 million, respectively, on the back of new geographic approvals and Galafold’s market penetration. Amicus incurred a cost of goods sold of $833,000 in 2016 compared to $6.2 million in 2017.
According to the American Journal of Human Genetics, newborn screening studies in Italy, Taiwan, and Austria found the incidence of Fabry disease mutations to be between 1:2,400 and 1:4,000—more than ten times higher than previous studies. At present, Galafold has two competitors: agalsidase beta and agalsidase alfa.
Amicus Therapeutics (FOLD) is currently developing a novel proprietary enzyme replacement therapy (or ERT) coformulated with migalastat HC1 for Fabry disease patients with nonamenable genetic mutations. The therapy is currently in late preclinical development. The future value driver of the company’s research pipeline is ATB200/AT2221, a novel, late-stage treatment for Pompe disease.
Amicus Therapeutics (FOLD) is a global patient-focused biotechnology company engaged in developing and commercializing diverse novel treatments for patients with rare metabolic diseases. As of April 2018, of the seven analysts covering Amicus Therapeutics, three have given the stock “strong buy” ratings, three have given it “buy” ratings, and one has given it a “hold” rating. The mean rating for the stock is 1.71 with a target price of $19.93, implying an upside of almost 45% to $13.79 as of its closing on April 24.
CRANBURY, N.J., April 26, 2018-- Amicus Therapeutics today announced a conference call and live audio webcast on Tuesday, May 8, 2018 at 8:30 a.m. ET to discuss financial results for the first quarter ...
Investors need to pay close attention to Amicus Therapeutics (FOLD) stock based on the movements in the options market lately.
UniQure (QURE) is a leading company in the field of gene therapy. It has a focused pipeline of innovative gene therapies developed both internally and through collaboration for cardiovascular diseases. It has established clinical proof of concept for its lead indication, hemophilia B, and has achieved preclinical proof of concept in Huntington’s disease.